Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Feb 01, 2021 1:44pm
174 Views
Post# 32438086

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Dumping 20M shares and keeping 10M warrants @$3.18

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Dumping 20M shares and keeping 10M warrants @$3.18I just envisioned the ultimate nightmare scenario - CYDY makes a hostile bid for THTX in order to acquire real drug prospects for CYDY. Acquiring THTX would be chump change for CYDY. Plus they would get actual revenues too. CYDY should actually a stock deal for THTX yesterday or sooner since they likely have nothing at all that will get approved. And if that happens, it would be something of a poetic ending for THTX. While hostile deals are verboten in biotech, I suspect this would not hinder CYDY. I assume I could count on all of you on this board to block such a crazy thing should that nightmare turn into reality, which it won't - I think!

SPCEO1 wrote: CYDY is the polar opposite of THTX. They are great at communicating a bad, perhaps bogus, story and THTX has a good story that they are unable to communicate effectively. Both companies are bad in their own ways and good in their own ways. Maybe they should merge! Just joking. I don't want THTX to become CYDY but they could learn a lot from how they communicate with this particular bubbly market.

scarlet1967 wrote: If transparency, active marketing, good communication and updating market is classed as corruption then the whole market is corrupted as CYDY is not the only company which has that strategy.


Bucknelly21 wrote: I'm curious about the cydy credibility argument, the market seems to trust them yet everyone here says corruption is the root of their company. The more I see things like this the less faith I have in Thtx to be honest. They get credit for everything they do yet we get nothing and we are apparently the squeaky clean company 

 




<< Previous
Bullboard Posts
Next >>